000 02402 a2200721 4500
005 20250515093422.0
264 0 _c20080326
008 200803s 0 0 eng d
022 _a1476-5551
024 7 _a10.1038/sj.leu.2405014
_2doi
040 _aNLM
_beng
_cNLM
100 1 _ade Lima, M
245 0 0 _aPhase I/II study of gemtuzumab ozogamicin added to fludarabine, melphalan and allogeneic hematopoietic stem cell transplantation for high-risk CD33 positive myeloid leukemias and myelodysplastic syndrome.
_h[electronic resource]
260 _bLeukemia
_cFeb 2008
300 _a258-64 p.
_bdigital
500 _aPublication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
650 0 4 _aAdolescent
650 0 4 _aAdult
650 0 4 _aAged
650 0 4 _aAminoglycosides
_xadministration & dosage
650 0 4 _aAntibodies, Monoclonal
_xadministration & dosage
650 0 4 _aAntibodies, Monoclonal, Humanized
650 0 4 _aAntigens, CD
650 0 4 _aAntigens, Differentiation, Myelomonocytic
650 0 4 _aAntineoplastic Combined Chemotherapy Protocols
_xtherapeutic use
650 0 4 _aDisease-Free Survival
650 0 4 _aFemale
650 0 4 _aGemtuzumab
650 0 4 _aGraft Survival
650 0 4 _aHematopoietic Stem Cell Transplantation
_xmethods
650 0 4 _aHumans
650 0 4 _aLeukemia, Myeloid
_xmortality
650 0 4 _aMale
650 0 4 _aMelphalan
_xadministration & dosage
650 0 4 _aMiddle Aged
650 0 4 _aMyelodysplastic Syndromes
_xmortality
650 0 4 _aRemission Induction
650 0 4 _aSialic Acid Binding Ig-like Lectin 3
650 0 4 _aSurvival Rate
650 0 4 _aTransplantation, Homologous
650 0 4 _aVidarabine
_xadministration & dosage
700 1 _aChamplin, R E
700 1 _aThall, P F
700 1 _aWang, X
700 1 _aMartin, T G
700 1 _aCook, J D
700 1 _aMcCormick, G
700 1 _aQazilbash, M
700 1 _aKebriaei, P
700 1 _aCouriel, D
700 1 _aShpall, E J
700 1 _aKhouri, I
700 1 _aAnderlini, P
700 1 _aHosing, C
700 1 _aChan, K W
700 1 _aAndersson, B S
700 1 _aPatah, P A
700 1 _aCaldera, Z
700 1 _aJabbour, E
700 1 _aGiralt, S
773 0 _tLeukemia
_gvol. 22
_gno. 2
_gp. 258-64
856 4 0 _uhttps://doi.org/10.1038/sj.leu.2405014
_zAvailable from publisher's website
999 _c17507422
_d17507422